GlassScriptPhysician profile
Jun-Ki Park
NPI 1861713471
$3,309.01
in general payments reported to CMS, 2019-2025
24 companies · $684 in 2025
The $684 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $140 · 2021: $353 · 2022: $451 · 2023: $599 · 2024: $692 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635 · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.75 |
| Education | $339.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $692.19 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Mallinckrodt Hospital Products INC. | $337.28 | 2021-2025 | Acthar |
| Akebia Therapeutics INC | $332.55 | 2019-2024 | Auryxia |
| Amgen INC. | $228.76 | 2019-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $201.31 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $176.24 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $154.16 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $144.07 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $137.41 | 2021-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $137.02 | 2021-2025 | Farxiga |
| Horizon Therapeutics Plc | $120.52 | 2021-2022 | |
| Vifor Pharma, INC. | $116.20 | 2019-2022 | |
| Novo Nordisk INC | $105.73 | 2021-2024 | Rybelsus, Ozempic |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $103.31 | 2019 | |
| Ardelyx, INC. | $77.29 | 2024-2025 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.40 | 2023 | Jardiance |
| Lilly USA, LLC | $47.87 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $27.14 | 2020 | |
| Calliditas Therapeutics US INC. | $22.97 | 2025 | Tarpeyo |
| Azurity Pharmaceuticals, INC. | $21.70 | 2023 | Edarbyclor |
| Supernus Pharmaceuticals, INC. | $19.74 | 2022 | |
| Shield Therapeutics INC | $19.56 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.95 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun-Ki Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.